FDA Approves New Schizophrenia Treatment
In a groundbreaking development, the Food and Drug Administration has authorized the use of Cobenfy, a novel medication for treating schizophrenia, set to be marketed by Bristol Myers Squibb. This twice-daily pill is notable for its reduced side effects, a critical consideration highlighted by patients dealing with the burdensome impacts of existing antipsychotic medications. Tiffany, an affected individual from Oklahoma, shared her struggle with treatments that left her feeling numb and disconnected from reality. Read more.
Call for Coherent Marijuana Policy to Safeguard Public Health
The evolving landscape of cannabis legalization across various states has prompted a leading group of scientists to advocate for comprehensive policy reforms. These measures aim to mitigate public health risks associated with fragmented regulations. As the legal cannabis market expands, ensuring consistent health safeguards is becoming increasingly vital to prevent adverse outcomes. Read more.
